GLP-1 medications entered the public conversation as weight loss drugs, and that reputation is well earned. But framing semaglutide and tirzepatide as appetite tools alone misses the bigger and far more exciting story unfolding in clinical research. Over the past two years, regulators have approved these medications for heart disease, kidney disease, sleep apnea, and liver disease, with active research now reaching into addiction medicine and brain health. What started as a metabolic therapy is turning into one of the most versatile drug classes in modern medicine.
At R3 Health, we view GLP-1 therapy through a functional and regenerative lens. These molecules do not simply suppress hunger. They act on receptors throughout the body, influencing inflammation, vascular function, organ stress, and metabolic signaling. That broad mechanism is exactly why the list of approved and investigational uses keeps growing. Here is where the science stands today.
Cardiovascular Protection
The cardiovascular story is the most established expansion beyond weight loss. In March 2024, the FDA approved semaglutide to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who also have obesity or overweight, making it the first weight management medication to also carry a cardiovascular event prevention indication [1].
The momentum continued in October 2025, when the FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk, including patients who have never had a prior cardiovascular event [2]. That approval rested on the phase 3b SOUL trial, which followed more than 9,600 adults and demonstrated a 14 percent relative reduction in the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke compared with placebo [3]. This made oral semaglutide the first GLP-1 medication available in pill form to earn a cardiovascular risk reduction indication, an important step for patients who want the benefits without injections [2].
Kidney Protection
The kidneys are deeply intertwined with metabolic and cardiovascular health, and GLP-1 therapy is now part of that conversation too. In January 2025, the FDA approved semaglutide (Ozempic) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [4].
The approval was driven by the FLOW trial, an international study of 3,533 adults that was stopped early once it met its efficacy targets. Participants treated with once-weekly semaglutide experienced a 24 percent relative reduction in the risk of major kidney disease events, end-stage kidney disease, and cardiovascular death compared with placebo [4]. Researchers attribute these benefits to mechanisms that go well beyond glucose control, including reduced glomerular stress, lower inflammation, and protection against the oxidative damage that drives kidney decline [5].
Sleep Apnea
In December 2024, the FDA approved tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, making it the first medication ever approved for this condition [6]. For a disorder long managed almost entirely with CPAP machines and oral appliances, this represented a genuine turning point in sleep medicine.
The approval came from the SURMOUNT-OSA trials, where tirzepatide reduced breathing disruptions by roughly 25 to 29 events per hour, compared with about 5 to 6 per hour on placebo [7]. A substantial share of participants saw their sleep apnea improve to mild levels or resolve, alongside body weight reductions of 18 to 20 percent [7]. The result is a treatment that addresses an underlying driver of the disease rather than only managing symptoms during sleep.
Liver Health
The liver is the newest organ to join the list. In August 2025, the FDA granted accelerated approval to semaglutide for adults with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced fibrosis, making it the first GLP-1 receptor agonist approved for this serious liver condition [8]. MASH, formerly known as NASH, is a progressive form of fatty liver disease that can lead to scarring and long-term liver complications.
The approval was based on part one of the ESSENCE trial. Among patients receiving semaglutide, roughly 63 percent achieved resolution of steatohepatitis without worsening fibrosis, compared with about 34 percent on placebo, and a meaningful share also saw improvement in liver scarring [9]. This marked the first time a GLP-1 medication demonstrated improvement in fibrosis itself, a key milestone in treating a disease that until recently had almost no pharmacologic options [9].
Emerging Frontiers: Addiction Medicine
Some of the most intriguing research is happening in addiction medicine. Clinicians began noticing that patients on GLP-1 therapy were drinking less, and that observation has now been tested in controlled trials. A 2025 randomized clinical trial published in JAMA Psychiatry found that low-dose semaglutide reduced alcohol craving and lowered the amount of alcohol consumed in adults with alcohol use disorder [10].
The signal strengthened in 2026, when a randomized, placebo-controlled trial published in The Lancet reported that adding once-weekly semaglutide to cognitive behavioral therapy produced robust reductions in heavy drinking among participants with alcohol use disorder and obesity [11]. Researchers believe GLP-1 receptors influence the brain’s reward pathways, which may explain why these medications appear to dampen cravings not only for food but for alcohol as well. Larger phase 3 trials are now underway to confirm these findings [11].
Emerging Frontiers: Brain Health
Brain health is the frontier where enthusiasm meets the need for patience. Observational data and the anti-inflammatory, neuroprotective mechanisms of GLP-1 therapy raised real hope that these medications might slow neurodegenerative disease. The large phase 3 EVOKE and EVOKE+ trials put that hypothesis to a rigorous test in nearly 3,800 adults with early-stage Alzheimer’s disease [12].
The results, reported in late 2025 and early 2026, were a reminder that promising biology does not always translate to clinical benefit. Oral semaglutide did not significantly slow disease progression compared with placebo, even though it improved several Alzheimer’s-related and inflammatory biomarkers and was well tolerated [12]. Research in Parkinson’s disease and other neurological conditions remains mixed and ongoing. The takeaway is encouraging in a measured way: the science continues, and each well-designed trial sharpens our understanding of where these medications can and cannot help.
What This Means for Whole-Person Care
The expanding GLP-1 story reflects a shift we embrace at R3 Health. The most powerful therapies are rarely single-purpose. When a medication can support cardiovascular health, protect the kidneys, improve sleep, and reverse early liver damage, it stops being a weight loss tool and becomes a metabolic and regenerative ally. The shared thread across all of these conditions is metabolic dysfunction and inflammation, the same upstream drivers that functional medicine works to address.
GLP-1 therapy is not right for everyone, and these medications work best as part of a comprehensive plan that includes nutrition, movement, and personalized clinical guidance. If you are curious about whether GLP-1 therapy fits your health goals, our team can help you understand the full picture and build a strategy around your individual needs.
References
- U.S. Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. March 2024.
- Novo Nordisk. FDA approves oral semaglutide (Rybelsus) for cardiovascular risk reduction in adults with type 2 diabetes at high risk. October 2025.
- McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL trial). New England Journal of Medicine. 2025;392(20):2001-2012.
- Novo Nordisk. FDA approves Ozempic (semaglutide) to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. January 28, 2025. Based on the FLOW trial, Perkovic V, Tuttle KR, Rossing P, et al. New England Journal of Medicine. 2025;392:345-356.
- Cherney DZI, et al. Renoprotective mechanisms of GLP-1 receptor agonists: beyond glucose lowering. Diabetes Care. 2024;47:2637-2649.
- U.S. Food and Drug Administration / Eli Lilly. FDA approves Zepbound (tirzepatide) as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024.
- SURMOUNT-OSA trial results, Eli Lilly. American Academy of Sleep Medicine statement on Zepbound approval for obstructive sleep apnea. 2024-2025.
- U.S. Food and Drug Administration / Novo Nordisk. Wegovy (semaglutide 2.4 mg) approved for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. August 15, 2025.
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). New England Journal of Medicine. 2025;392(21):2089-2099.
- Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395-405.
- Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomized, double-blind, placebo-controlled trial. The Lancet. 2026.
- Cummings J, et al. Efficacy and safety of oral semaglutide in early-stage symptomatic Alzheimer’s disease (EVOKE and EVOKE+): two phase 3, randomized, placebo-controlled trials. Presented at the Clinical Trials on Alzheimer’s Disease conference, December 2025; published in The Lancet, 2026.
